Roche Unveils Rapid PCR Test for Bundibugyo Ebola Virus to Meet Emergency Needs

Roche's Rapid Development of PCR Test for Ebola Bundibugyo Virus

In an exceptional display of speed and efficiency, pharmaceutical giant Roche has successfully developed a PCR test specifically designed to detect the rare Bundibugyo virus, a strain of Ebola. Completing the test within a remarkable six days after the genome sequence was published, Roche is bolstering efforts to combat the current outbreak in Central and East Africa.

This new molecular PCR test, created by Roche's subsidiary TIB MOLBIOL, targets the unique features of the Bundibugyo virus and is designed for use on various advanced diagnostic platforms like the LightCycler® 480 I/II Systems and the cobas® z 480 analyzer. Given the urgent need for effective diagnostic tools amidst ongoing outbreaks, the test is aimed at helping laboratories quickly establish testing capabilities to enhance containment efforts.

In light of the World Health Organization's (WHO) classification of the outbreak as a Public Health Emergency of International Concern in mid-May 2026, Roche's swift response showcases its commitment to addressing critical health needs in affected communities. The Bundibugyo virus is particularly concerning due to its significant case fatality rate and the lack of approved vaccines or treatments. With historical fatality rates ranging between 30% to 50%, the rapid detection of this virus is vital for timely medical intervention and outbreak management.

Dr. Marcus Droege, CEO of TIB MOLBIOL, emphasized the importance of a quick response during outbreak situations, stating, "Diagnostics are among the first vital tools needed." This new Research Use Only (RUO) assay aims to facilitate early-stage outbreak responses, support public health surveillance, and assist in swift decision-making processes.

TIB MOLBIOL is strategically equipped for outbreak responses, as evidenced by its extensive library of over 15,000 pre-designs for various pathogens. The facility is adept at mobilizing resources rapidly upon identification of an outbreak, allowing for the evaluation of multiple primer and probe combinations in mere hours. This capability is crucial for generating effective diagnostic solutions without delay, particularly in light of the alarming transmissibility of the Bundibugyo virus.

The validation of this new test is carried out using real clinical samples within TIB MOLBIOL's network of reference laboratories, ensuring accuracy and reliability in its performance. Roche is working in conjunction with local public health authorities to ensure that these tests reach laboratories on the frontlines of the outbreak, enhancing the testing capacity in regions most affected.

Historically, PCR testing has played a monumental role in controlling Ebola outbreaks, proving indispensable during the 2014–2016 West Africa epidemic. Roche's adeptness in epidemic response has also been showcased through its past rapid-response solutions, which include tests for diseases such as Covid-19, ZIKA, and H1N1 swine flu. The latest development reflects Roche's dedication to innovative solutions in the face of emerging health threats.

With no licensed vaccines or treatments available, the availability of the PCR test represents a significant step towards mitigating the risks associated with this deadly virus. The global health community has been alerted to the critical nature of swift testing and improved diagnostic strategies. Roche's initiatives not only enhance outbreak preparedness but also affirm its long-held partnership with healthcare systems across Africa. Their commitment to strengthening healthcare infrastructure plays a pivotal role in equipping regions to tackle infectious diseases more effectively.

As Roche continues to develop solutions for infectious diseases, the focus remains on maintaining strong collaborations with healthcare entities, ensuring equitable access to diagnostic tools, and ultimately protecting public health during crises.

For further information about the PCR test and Roche's ongoing efforts in combating infectious diseases, visit www.diagnostics.roche.com.